- 107studies, of 27,380 in the library
- 107peer-reviewed
- 2002–2026years published
- 50median usefulness score out of 100
These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news.
How the records spell this journal (2 spellings)
- Molecular Psychiatry — 6 studies
- Molecular psychiatry — 101 studies
The 20 highest-scoring
- Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53949)
- Whole-genome sequencing reveals novel ethnicity-specific rare variants associated with Alzheimer's disease
-
A novel Alzheimer disease locus located near the gene encoding tau protein
Because APOE ɛ4 "may mask effects of other loci," this study looked separately at people without ɛ4 and found a new genome-wide significant signal in a region of chromosome 17 near MAPT, the gene for tau protein, where one SNP (rs2732703) accounted for the whole signal. The same variants were linked to activity of the nearby KANSL1 gene, and more weakly MAPT, in brain tissue, and an early-stage analysis suggested APOE may interact with a TMEM106B variant previously tied to frontotemporal dementia. The authors say the result needs replication in independent samples before the region's role is confirmed; it points to where to look, not to a treatment.
- Associations between trajectories of plasma biomarkers for Alzheimer's disease, brain structures, and cognitive function: a prospective cohort study in the UK Biobank
-
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative
In more than 1000 people from the Alzheimer's Disease Neuroimaging Initiative, blood p-tau181 was already raised before symptoms in people with amyloid on PET and rose further in mild cognitive impairment and Alzheimer's dementia. It separated Alzheimer's dementia well (AUC 85.3%) but amyloid-positive from amyloid-negative people less well (AUC 76.9%), and higher baseline levels predicted later dementia about as well as the spinal-fluid p-tau181 test. These are group-level results from a research cohort with no stated cut-off, so they do not show that one blood result can diagnose or forecast Alzheimer's in an individual.
-
African ancestry GWAS of dementia in a large military cohort identifies significant risk loci
This genome-wide association study in an African descent cohort found significant associations in the region of APOE, in ROBO1, and in RNA RP11-340A13.2, with additional signals near known risk genes in a meta-analysis. These are genetic risk findings and do not show how to treat, cure, or prevent Alzheimer's disease.
- Genome-wide association study provides insights into the genetic basis of Lewy body dementia
- Multi-ancestry meta-analysis and fine-mapping in Alzheimer's disease
-
Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
This study found that a genetic variant upstream of the BIN1 gene increased BIN1 expression and Alzheimer's disease risk, and that the variant was linked to tau but not amyloid loads in brains. The authors propose BIN1 affects risk by influencing tau pathology.
-
Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review
This systematic review searched Medline, Embase and PsychINFO up to 23 February 2017 for studies that measured markers of microglia, the brain's main immune cells, in post-mortem brain tissue from people with Alzheimer's disease compared with aged people without neurological disease. It found 113 such articles, and its aim was to test whether raised microglia markers are a consistent feature of Alzheimer's brains. It looks only at brain tissue after death and reports no treatment, cure or prevention.
-
Neuroinflammatory fluid biomarkers in patients with Alzheimer's disease: a systematic literature review
Reviewing 54 studies, the authors found that inflammation markers in body fluids track different stages of Alzheimer's: spinal fluid YKL-40 was raised in Alzheimer's dementia, sTREM2 was more tied to early stages, and blood GFAP was raised both in dementia and in people with amyloid but no symptoms. Changes in blood GFAP over time appeared to predict cognitive decline. The authors say more long-term studies are needed before these markers are used routinely for diagnosis and monitoring.
- Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
- Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease
-
Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease
This genome-wide interaction study in 678 Alzheimer's Disease Neuroimaging Initiative participants looked for genetic factors that modify the relationship between brain beta-amyloid burden and cognitive impairment. The authors note that beta-amyloid is necessary for the pathologic diagnosis of Alzheimer's disease but is not sufficient to cause dementia.
- Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study
-
Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
This study compared cerebrospinal fluid and imaging markers in 282 patients to see which best predicted cognitive decline. It found that tau PET best predicted decline, and that while amyloid results were similar using fluid or imaging, results for tau and neurodegeneration were not interchangeable.
-
The neuropathological profile of mild cognitive impairment (MCI): a systematic review
This systematic review of 162 studies found that mild cognitive impairment is neuropathologically complex, involving plaque and tangle formation, vascular pathologies, inflammation, oxidative stress and other changes, and cannot be understood within a single framework. It identifies what still requires further research and offers no treatment, cure or prevention.
-
Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology
Using fruit flies, this study screened 296 constructs targeting 54 candidate Alzheimer's risk genes and found that PTK2B acts as an early marker and in vivo modulator of tau toxicity. The human tau and PTK2B proteins interacted in vitro and co-localized with abnormal tau in Alzheimer's patient brains and transgenic tau mice, but this is early laboratory and animal work.
-
Peripheral immunity is associated with the risk of incident dementia
In over 361,000 UK Biobank participants, markers of peripheral immunity were associated with the risk of developing dementia. This links immune markers to dementia risk but does not test whether modifying immunity prevents dementia.
-
Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s disease
In 457 participants, elevated and faster-rising plasma p181 levels in amyloid-positive individuals with subjective cognitive decline predicted cognitive decline and transition to mild cognitive impairment. This is a biomarker study supporting staging and risk identification, not a test of any treatment, cure, or prevention for Alzheimer's disease.
See all 107 studies, with filters →
Newest additions
- Assessing the de novo paradigm in sporadic early-onset Alzheimer disease trios
- Comprehensive single-cell transcriptomic atlas of microglia in Alzheimer's disease mouse models
- TREM2 in neurodegeneration and diseases
- The short-chain fatty acid butyrate prevents gut-brain amyloid-β pathology and neuroinflammation in an Alzheimer mouse model
- Frontotemporal dementia patient-derived iPSC neurons show cell pathological hallmarks and evidence for synaptic dysfunction and DNA damage
- Plasma neurofilament light reflects more severe manifestation of Alzheimer's disease in men
- Differential associations of APOE and TREM2 variants with glial fibrillary acidic protein and neurofilament light in plasma of UK Biobank participants support distinct disease mechanisms
- Cell autonomous microglia defects in a stem cell model of frontotemporal dementia tau
- The role of plasma inflammatory markers in late-life depression and conversion to dementia: a 3-year follow-up study
- Alzheimer's disease biomarkers and their current use in clinical research and practice
By review status
- Peer-reviewed — 107